抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3166人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852914, encodeId=d13d1852914a7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒, objectType=article, longId=301104, objectId=bf1030110428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1030110428, replyNumber=0, likeNumber=68, createdTime=2022-12-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1030110428, moduleTitle=J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1030110428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852753, encodeId=522e1852e53f2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JNCI：免疫检查点抑制剂治疗的癌症患者的生活质量, objectType=article, longId=217178, objectId=1cec21e17813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cec21e17813, replyNumber=0, likeNumber=97, createdTime=2021-10-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cec21e17813, moduleTitle=JNCI：免疫检查点抑制剂治疗的癌症患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cec21e17813)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852775, encodeId=1a9c1852e75eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JCI：无需节食和运动！“PDE5抑制剂的表哥”能够刺激脂肪燃烧，促进减肥, objectType=article, longId=218385, objectId=cebf2183855e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cebf2183855e, replyNumber=0, likeNumber=74, createdTime=2022-07-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cebf2183855e, moduleTitle=JCI：无需节食和运动！“PDE5抑制剂的表哥”能够刺激脂肪燃烧，促进减肥, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cebf2183855e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852878, encodeId=ddb818528e869, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Stroke：选择性5-羟色胺再摄取抑制剂与非心源性缺血性卒中风险的关系, objectType=article, longId=295132, objectId=a31029513287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a31029513287, replyNumber=0, likeNumber=69, createdTime=2022-07-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a31029513287, moduleTitle=Stroke：选择性5-羟色胺再摄取抑制剂与非心源性缺血性卒中风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a31029513287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852951, encodeId=85241852951ab, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Rheumatol：类风湿性关节炎使用不同JAK抑制剂发生严重感染的风险并无显著差异, objectType=article, longId=724921, objectId=d518e24921e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d518e24921e1, replyNumber=0, likeNumber=89, createdTime=2022-10-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d518e24921e1, moduleTitle=J Clin Rheumatol：类风湿性关节炎使用不同JAK抑制剂发生严重感染的风险并无显著差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d518e24921e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852992, encodeId=e4ce1852992f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, objectType=article, longId=729096, objectId=317ae2909688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317ae2909688, replyNumber=0, likeNumber=81, createdTime=2023-04-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317ae2909688, moduleTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317ae2909688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852947, encodeId=4d2d185294efb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤, objectType=article, longId=724283, objectId=8cc1e24283bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cc1e24283bf, replyNumber=0, likeNumber=77, createdTime=2022-07-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cc1e24283bf, moduleTitle=J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cc1e24283bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852910, encodeId=fea818529103a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ARD: COVID-19 疫苗对服用免疫抑制剂的患者的疗效, objectType=article, longId=300840, objectId=8c4f30084066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c4f30084066, replyNumber=0, likeNumber=66, createdTime=2022-09-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c4f30084066, moduleTitle=ARD: COVID-19 疫苗对服用免疫抑制剂的患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c4f30084066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852976, encodeId=133b18529e650, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究, objectType=article, longId=727689, objectId=c057e27689e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c057e27689e7, replyNumber=0, likeNumber=76, createdTime=2022-10-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c057e27689e7, moduleTitle=HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c057e27689e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853016, encodeId=bb6d18530161f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Hypertension：RAAS抑制剂可显著降低高血压患者脑动脉瘤的破裂风险, objectType=article, longId=731842, objectId=7c41e31842d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c41e31842d7, replyNumber=0, likeNumber=91, createdTime=2023-03-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c41e31842d7, moduleTitle=Hypertension：RAAS抑制剂可显著降低高血压患者脑动脉瘤的破裂风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c41e31842d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852777, encodeId=76ef1852e7706, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Immunother Cancer：免疫检查点抑制剂在伴有牛皮癣患者的疗效和安全性, objectType=article, longId=218548, objectId=8a8921854861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a8921854861, replyNumber=0, likeNumber=87, createdTime=2022-05-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a8921854861, moduleTitle=J Immunother Cancer：免疫检查点抑制剂在伴有牛皮癣患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a8921854861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852879, encodeId=493718528e9f0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, objectType=article, longId=295140, objectId=2fc82951409c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc82951409c, replyNumber=0, likeNumber=60, createdTime=2022-04-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc82951409c, moduleTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc82951409c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852981, encodeId=926a18529810e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=69, createdTime=2022-09-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852946, encodeId=ca91185294608, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Ann Intern Med：心衰患者钠-葡萄糖共转运蛋白2抑制剂的效果分析, objectType=article, longId=724158, objectId=a7abe24158f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7abe24158f2, replyNumber=0, likeNumber=98, createdTime=2022-09-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7abe24158f2, moduleTitle=Ann Intern Med：心衰患者钠-葡萄糖共转运蛋白2抑制剂的效果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7abe24158f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852980, encodeId=c2f5185298089, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效, objectType=article, longId=727632, objectId=94b4e2763255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b4e2763255, replyNumber=0, likeNumber=92, createdTime=2022-11-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b4e2763255, moduleTitle=BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94b4e2763255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852978, encodeId=362d18529e8e9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAMA Oncol：5α-还原酶抑制剂与前列腺癌死亡率的相关性, objectType=article, longId=727896, objectId=1a13e27896e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a13e27896e5, replyNumber=0, likeNumber=77, createdTime=2022-10-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a13e27896e5, moduleTitle=JAMA Oncol：5α-还原酶抑制剂与前列腺癌死亡率的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a13e27896e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852849, encodeId=282518528490e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性, objectType=article, longId=292745, objectId=425c292e45ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=425c292e45ea, replyNumber=0, likeNumber=79, createdTime=2022-07-08, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=425c292e45ea, moduleTitle=Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=425c292e45ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852872, encodeId=bcbc18528e235, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clinical Lung Cancer：新冠疫情影响下免疫检查点抑制剂（ICI）的延迟给药并不影响NSCLC患者的疗效, objectType=article, longId=294168, objectId=9ceb29416816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ceb29416816, replyNumber=0, likeNumber=62, createdTime=2022-05-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ceb29416816, moduleTitle=Clinical Lung Cancer：新冠疫情影响下免疫检查点抑制剂（ICI）的延迟给药并不影响NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ceb29416816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852835, encodeId=2975185283585, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=基因编辑技术可100%控制后代性别，新型HIV感染抑制剂可提供长期保护丨一周科技导读, objectType=article, longId=264982, objectId=197a26498282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=197a26498282, replyNumber=0, likeNumber=0, createdTime=2022-09-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=197a26498282, moduleTitle=基因编辑技术可100%控制后代性别，新型HIV感染抑制剂可提供长期保护丨一周科技导读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=197a26498282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852762, encodeId=65571852e62d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=信达生物(01801)与UNION达成战略合作引进用于治疗炎症性皮肤病的下一代PDE4抑制剂, objectType=article, longId=217823, objectId=dc8421e823de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc8421e823de, replyNumber=0, likeNumber=70, createdTime=2022-05-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc8421e823de, moduleTitle=信达生物(01801)与UNION达成战略合作引进用于治疗炎症性皮肤病的下一代PDE4抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc8421e823de)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Am Acad Dermatol：外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒

2022-12-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JNCI：免疫检查点抑制剂治疗的癌症患者的生活质量

2021-10-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JCI：无需节食和运动！“PDE5抑制剂的表哥”能够刺激脂肪燃烧，促进减肥

2022-07-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Stroke：选择性5-羟色胺再摄取抑制剂与非心源性缺血性卒中风险的关系

2022-07-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Rheumatol：类风湿性关节炎使用不同JAK抑制剂发生严重感染的风险并无显著差异

2022-10-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！

2023-04-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤

2022-07-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ARD: COVID-19 疫苗对服用免疫抑制剂的患者的疗效

2022-09-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

HAEMATOLOGICA：慢性粒细胞白血病患者停用酪氨酸激酶抑制剂后的疼痛报告研究

2022-10-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Hypertension：RAAS抑制剂可显著降低高血压患者脑动脉瘤的破裂风险

2023-03-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Immunother Cancer：免疫检查点抑制剂在伴有牛皮癣患者的疗效和安全性

2022-05-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？

2022-04-19

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2022-09-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Ann Intern Med：心衰患者钠-葡萄糖共转运蛋白2抑制剂的效果分析

2022-09-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效

2022-11-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAMA Oncol：5α-还原酶抑制剂与前列腺癌死亡率的相关性

2022-10-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性

2022-07-08

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clinical Lung Cancer：新冠疫情影响下免疫检查点抑制剂（ICI）的延迟给药并不影响NSCLC患者的疗效

2022-05-20

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

基因编辑技术可100%控制后代性别，新型HIV感染抑制剂可提供长期保护丨一周科技导读

2022-09-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

信达生物(01801)与UNION达成战略合作引进用于治疗炎症性皮肤病的下一代PDE4抑制剂

2022-05-12

科室
- - 订阅+
  - 更多科室
工具
服务